Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17592647 | 1.00 | NCF1 (0.37) | NCF1SMN1; SMN2PLGPLATLMNA | |
| SCHEMBL17592192 | 1.00 | NCF1 (0.37) | NCF1SMN1; SMN2PLGPLATLMNA | |
| SCHEMBL8284727 | 0.89 | SMN1; SMN2 (0.48) | NCF1SMN1; SMN2PLGPLATLMNA | |
| SCHEMBL127998 | 0.89 | — | — | |
| SCHEMBL16108499 | 0.89 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL20337441 | 0.83 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9645385 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9645379 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9645375 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL14039649 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | claimed |
| US-10301263-B2 | Anticonvulsant compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-05-28 | — | — | US | disclosed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | NCF1 3434/4885SMN1; SMN2 1964/4885PLG 1367/4885 |
| US-10301263-B2 | Anticonvulsant compound | PSEN2, BACE2, APP | NCF1 3341/4885SMN1; SMN2 2134/4885PLG 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.